A method of treating urogenital infections

 

(57) Abstract:

The invention relates to medicine, in particular to urology, and is aimed at improving the treatment of infections of bacterial, viral and mixed etiology. This goal is achieved by the fact that etiotropic therapy is the infusion of a synthetic polypeptide of bahlocation related to a new class of drugs - tipatina. Introduction it is carried out in a mode in relation to the conduct of etiotropic therapy of antibiotics in combination with cytokines. The method allows to suppress the causal factor of the disease. table 1.

The invention relates to medicine, in particular to urology, and can be used to treat infections of bacterial, viral and mixed etiology.

Known and currently used for the treatment of viral infections medicines such as acyclovir, methisazone, rimantadine (Mashkovsky M. D. Medicines. H 2. - M.: Medicine, 1998. - S. 396 and 397).

The closest analogue of the claimed method of treatment of urogenital infections is a combination of causal and immunomodulary acyclovir at a dose of 1.2 g per day for 10 days, and cytokines, such as interferon in topical applications in the form of a tampon on ME 5 for 14-28 days (Kozlova Century. And., Puchner A. F. Viral, chlamydial and mycoplasmal diseases of the genitals: a Guide for the doctor. - M.: Avicenna, 1995. - S. 135).

In the treatment of chlamydial infection using a combination of antibiotics of the tetracycline group, such as stigmatizing, per os on the 125,000 UNITS 4 times daily for 30 days with cytokines, such as interferon, in topical applications in the form of a tampon on ME 5 for 14-28 days (ibid, S. 225).

However, the authors note the low efficacy of this therapy. Only 14% of patients achieved clinical and laboratory recovery, 70% was achieved clinical remission for 2-3 weeks, 16% of the treatment was without effect. In addition, long-term intravaginal introduction of tampons for the majority of patients has resulted in irritation of the mucous membrane, 40% caused allergic reactions in 6% joined secondary infection.

The aim of the invention is to increase the efficiency of treatment of urogenital infections with elimination in the body causal factor.

This objective is achieved in that for 5-7 days before treatment, during and 5-7 days after the end of the por is whether drugs containing this compound, at a dose of 10-30 mg intramuscularly.

The invention is illustrated in the following examples.

Example 1.

Patient K., aged 27, was asked for advice. Complaints of recurrent lesions in the genital area, genital itching.

From the anamnesis it is known that childhood was worried about the rash of herpes face, herpes in the genital area first appeared 1.5 years ago, after the birth. Treated folk remedies: douching with an infusion of chamomile, without effect. A year ago, due to increased frequency of exacerbations and frequency of genital lesions in 4-6 weeks, took acyclovir 1.2 g per day for 7 days, as a result of treatment achieved remission at 1 month. During treatment, blood was recorded herpes simplex virus types 1 and 2 (hereinafter referred to HSV-1, HSV-2), increased antibody titer to them.

Examination: the right physique, the skin is a normal color. Inguinal lymph 1.5 cm in diameter, dense, painful on palpation, the skin is not welded. Large labia are not changed. The mucosa of the small labia hyperemic, edematous, 5 vesicles with clear content. In the field of perineal excoriation, traces of scratches. The organs and systems without the -2 type - 15 times. Detected in the urine DNA of HSV-2 type.

Complaints of the patient, changes in the oral mucosa of the genitals, reactive state of regional lymph nodes, the higher titer of antibodies to HSV-1 and HSV-2, detection of the pathogen in the urine is characteristic lesions of herpes simplex virus type 2.

The diagnosis of genital herpes (HSV-2), acute stage.

Assigned treatment:

bis-(gamma-L-glutamyl)-L-cysteinyl-bis-glycine disodium salt intramuscular injection, 20 mg - 90 days;

acyclovir - oral, 200 mg 5 times a day - 7 days (from 10 to 17 days).

On day 3 of treatment vesicles covered with scabs, redness and swelling of the labia minora markedly decreased. Inguinal lymph 1.5 cm, dense, painless. During treatment was achieved clinical remission: stopped itching of the genitals, complete regression of herpetic lesions. Regional lymph nodes decreased to 1 cm in diameter, normal consistency, painless. The patient noted increasing efficiency, improving sleep. Any discomfort with the introduction of drugs notes. Blood - decrease in the level of antibodies to HSV-1 and HSV-2. DNA virus HSV-2 is not detected, which is evidence of clinical and laboratory remission.

Example 2.

Patient P. , 19 years old, came for a consultation with complaints of General weakness, body temperature rise up to 37,6oC, the selection drop of pus in the morning urination ("morning drop"), a small burning sensation in the urethra. At survey: asthenic physique, skin and mucous normal color, no rash. Hole urethral canal moderately hyperemic. Right enlarged inguinal lymph nodes up to 2 cm, palpation of the painful, the skin is not soldered. The organs and systems without features. Blood titer antibodies to chlamydia thrachomatis 9 times. Detected in the urine Chlamidia thrachomatis.

The clinical picture of the disease and the results of laboratory studies characteristic of chlamydial urogenital infections.

The diagnosis of chlamydial urethritis, acute.

Assigned treatment:

the complex bis-(gamma-L-glutamyl)-L-cysteinyl-bis-glycine disodium salt with inosine - injection, 30 mg - 60 days;

oxytetracycline - oral, 250000 IU 4 times a day for 20 days.

On the 5th day of l is r.e: skin and mucous normal color, rash no. Hole urethral channel normal color, no discharge. Inguinal lymph nodes are not palpable. Blood - decrease in the titer of antibodies to chlamydia thrachomatis, urinary pathogen not detected. During treatment, the patient noted improvement with health. Any unpleasant reactions during the administration of drugs notes.

At follow-up one month after the end of treatment clinical and laboratory manifestations of the disease completely disappeared. The painless urination, no discharge, lymph nodes are not palpable. Skin and visible mucous membranes normal color, no rash. Blood titer of antibodies to chlamydia thrachomatis promoted 3 times in urine pathogen is not defined.

Example 3.

Patient P., 19 years old, came for advice. Complaints of weakness, frothy allocation of yellow color of the genitals, itching of the perineum.

Complaints appeared 2 weeks ago. Treated with tetracycline 2 tabs. 7 days, no effect.

Examination: the right physique, the skin is a normal color. Mucous genital redness, enlarged inguinal lymph nodes up to 2 cm, painless, skin is not soldered. On linen - highlight yellow, with a pungent smell. The neck mA is e selection with a pungent smell.

From the scraping of the vaginal mucosa selected Mycoplasma in the blood increased levels of antibodies in 5 times.

The diagnosis of Mycoplasma genitalia.

Assigned treatment:

the complex bis-(gamma-L-glutamyl)-L-cysteinyl-bis-glycine disodium salt with inosine - injection, 30 mg - 30 days;

tetracycline is an oral, 0.3 g of 5 times in day of 10 days.

After 10 days clinical manifestations of the disease have disappeared completely by the end of the course mucous genitals normal color, inguinal lymph nodes are not enlarged, no discharge. Bacteriological examination of Mycoplasma was not found. Pronounced clinical and laboratory cure.

Example 4.

Patient M. , 24 years old, came for a consultation with complaints of General weakness, the selection drop of pus in the morning urination ("morning drop"), a small burning sensation in the urethra, lacrimation, pain in the eyes. At survey: asthenic physique, skin and mucous normal color, no rash. Conjunctiva of the eye redness. Hole urethral canal moderately hyperemic. Right enlarged inguinal lymph nodes up to 2 cm, palpation of the painful, the skin is not soldered. According to the authorities, and si is SS="ptx2">

The clinical picture of the disease and the results of laboratory studies characteristic of chlamydial urogenital infections.

The diagnosis of chlamydial urethritis, conjunctivitis, acute.

Assigned treatment:

the complex bis-(gamma-L-glutamyl)-L-cysteinyl-bis-glycine disodium salt with inosine - intramuscular injection, 10 mg - 30 days;

ciprofloxacin oral, 0.25 g 4 times a day to 20 days, from the 6th to the 25th.

On the 5th day of treatment, the patient noted the disappearance of pain during urination, stopping the allocation of pus in the morning. On examination: skin and mucous normal color, no rash. The symptoms of conjunctivitis disappeared. Hole urethral channel normal color, no discharge. Inguinal lymph nodes are not palpable. Blood - decrease in the titer of antibodies to chlamydia thrachomatis, urinary pathogen not detected. During treatment, the patient noted improvement with health. Any unpleasant reactions during the administration of drugs notes.

At follow-up one month after the end of treatment clinical and laboratory manifestations of the disease completely disappeared. The painless urination, no discharge, lymph nodes are not palpable. Skin and visible mucous is allocated.

Treatment infections of the claimed method is not obvious for a wide range of specialists. Traditionally for the treatment of urogenital infections assign causal funds in monotherapy or combined with immunomodulators. For example, for the treatment of diseases caused by HSV-1 or HSV-2 acyclovir for the treatment of chlamydia infection - tetracycline antibiotics. As an immunomodulator used interferon. It was believed that specific drugs inhibit the intracellular multiplication of microorganisms, interferon blocks replication by binding with receptors on the cell surface. To create therapeutic concentrations within infected cells have traditionally been considered necessary to increase the dose of a drug and the duration of its introduction, which led to an increase in side effects.

In the present method uses the connection with a different mechanism of action, and it initiates the apoptotic death of containing intracellular parasites of cells. Thus, the combined effects of specific drugs and apoptotic death of cells lead to the impossibility of reproduction of the virus intracellular, urea specific therapy.

This effect in the treatment of urogenital infections were not used. Obvious is also that of bis-(gamma-L-glutamyl)-L-cysteinyl-bis-glycine disodium salt should be used in the above combination and sequence, not in the order monotherapy.

The total reduction course doses of cytokines (interferon and antiviral drugs with high toxicity, in combination with the hepatoprotective effect of bis-(gamma-L-glutamyl)-L-cysteinyl-bis-glycine disodium salt leads to decrease the frequency and severity of side effects (see table).

The claimed method has important socio-economic importance as viral and bacterial lesions of the human reproductive system leading to infertility mother or intrauterine infection of the fetus and the birth of a child with severe developmental disabilities.

A method of treating urogenital infections bacterial, viral and mixed etiology with application of etiotropic drugs, characterized in that for 5 - 7 days before treatment, during and 5 to 7 days after application of causal means to the patient within 30 - 90 days to introduce bis-(gamma-L-glutamyl)-L-cysteinyl-bis-glycine

 

Same patents:
The invention relates to medicine, in particular to endocrine gynecology, and for the treatment of anovulatory infertility

The invention relates to medicine, namely to andrology, and can be used for the treatment of autoimmune male infertility

The invention relates to medicine, namely to dermatology and gynecology, and for the treatment of chronic, torpidly flowing forms of urogenital candidiasis in women

The invention relates to medicine, specifically to gynecology, and can be used for pharmacological correction of abnormalities in the immune system, namely immune deficiency in acute inflammatory diseases of the uterus

The invention relates to tricyclic pyrazole derivative of the General formula I, where R1-R4denote hydrogen, halogen, lower alkyl or lower alkoxy; R5denotes lower alkyl; R6denotes hydrogen, lower alkyl or lower alkoxy; X represents -(CR7R8)nor-CH=CH-; R7and R8represent hydrogen or lower alkyl and n = 1 or 2, or pharmaceutically applicable salts of basic compounds of General formula (I)

The invention relates to medicine, namely to gynecology

The invention relates to the field of veterinary obstetrics and gynecology, and can be used for the treatment of endometritis in cows
The invention relates to the field of medicine, technology of medicinal forms with bacterial drugs
The invention relates to medicine, technology of medicinal forms with bacterial drugs

The invention relates to therapeutic tools, specifically setidentityproviderid N-substituted nitrogenous heterocyclic compounds and methods of producing such compounds, intermediate products used in obtaining, compositions containing such compounds and the use of such heterocycles

The invention relates to compounds of formula I and their pharmaceutically acceptable salts, where the substituent R represents a halogen - C1-C8-alkyl, halogen - (C2-C8alkenyl, halogen - C2-C8-quinil or halogen - C1-C8-alkyl, substituted hydroxy or C1-C8-alkoxygroup; R1represents a hydrogen atom, halogen atom or C1-C8-alkoxygroup; or R and R1together with the two carbon atoms common to the benzene ring, form a condensed C4-C6-cycloalkyl, where one carbon atom is optionally replaced by oxygen atom, and where one or two carbon atoms optionally have up to five substituents selected from a halogen atom, a C1-C6-alkyl and halogen - (C1-C6-alkyl; X represents a C1-C6-alkoxy-, halogen - C1-C6-alkoxy, fenoxaprop or halogen atom; and Ar represents a phenyl group optionally substituted by a halogen atom

Rectal tool // 2152204
The invention relates to medicine and pharmaceutical industry and for the creation of new drugs used for the treatment of acute and chronic prostatitis

The invention relates to medicine, namely to methods of conservative treatment of children with renal dysplasia

The invention relates to (S)-(-)-2-trifluoromethyl-4-(3-cyanophenyl)-4,6,7,8-tetrahydro-5(1H)-chinolone and its pharmaceutically acceptable salts that can be used to treat urinary incontinence

The invention relates to medicine, in particular to infectious immunology, and is aimed at improving the treatment of viral hepatitis
Up!